Weight Management

Overview

Peptide-based weight management encompasses GLP-1/GIP/glucagon receptor agonists for appetite suppression and metabolic regulation, growth hormone peptides for body composition, and mitochondrial activators for metabolic rate enhancement. Modern triple-receptor agonists like Retatrutide represent the most powerful pharmacological weight loss tools available. Lifestyle and dietary interventions remain essential complements.

Recommended Peptides

• Retatrutide – triple agonist (GLP-1/GIP/glucagon); most powerful weight loss peptide currently available; 24% body weight reduction in trials
• Semaglutide – GLP-1 agonist; 15% body weight reduction; also cardiovascular protective; Ozempic/Wegovy
• Tirzepatide – GLP-1/GIP dual agonist; 20-22% body weight reduction; Mounjaro/Zepbound
• CagriSema – combination of cagrilintide (amylin analogue) and semaglutide; additive satiety signals
• AOD-9604 – growth hormone fragment targeting fat metabolism without GH side effects; lipolytic
• 5-Amino-1MQ – small molecule NNMT inhibitor; blocks fat storage enzyme and activates metabolic pathways
• MOTS-C – mitochondrial peptide improving insulin sensitivity and metabolic flexibility; exercise-mimetic effects
• SLU-PP-332 – ERR agonist; acts as exercise mimetic to increase metabolic rate and fat oxidation
• Survodutide – dual GLP-1/glucagon receptor agonist; 14.9% weight loss at 46 weeks; investigational (Boehringer Ingelheim)
• Mazdutide – dual GLP-1/glucagon receptor agonist; 14% weight loss at 48 weeks; approved in China (Innovent/Lilly)
• Tesofensine – triple monoamine reuptake inhibitor; centrally acting appetite suppressant
• Tesamorelin – GHRH analogue; reduces visceral fat and improves body composition via GH axis
• BAM15 – small molecule mitochondrial uncoupler; increases energy expenditure without appetite suppression; preclinical only (NOT a peptide)

Protocols

• Weight Loss Protocol
• Metabolic Reset Protocol

Related Conditions

• Fat Loss
• Metabolic Syndrome
• Type 2 Diabetes
• NAFLD
• Sarcopenia

Research Summary

Semaglutide has the strongest evidence base: the STEP trial series demonstrated 15-17% weight loss (STEP 1, PMID-33567185), sustained at 2 years (STEP 5, PMID-36216945), with cardiovascular benefit (SELECT, PMID-37952131). Oral semaglutide 50mg also showed significant weight loss (OASIS 1, PMID-37385278). Retatrutide achieved up to 24% weight loss in Phase 2 (PMID-37366315). AOD-9604 and 5-Amino-1MQ have preclinical evidence only. MOTS-C showed exercise-mimetic benefits in aged mice (PMID-33473109).

Related

• Condition Index
• Protocol Index

#condition #metabolic-system